Journal of Endocrinological Investigation最新文献

{"title":"Association between type 2 diabetes and depressive symptoms after a 1-year follow-up in an older adult Mediterranean population","authors":"I. Baenas, L. Camacho-Barcia, R. Granero, C. Razquin, D. Corella, C. Gómez-Martínez, O. Castañer-Niño, J. A. Martínez, Á. M. Alonso-Gómez, J. Wärnberg, J. Vioque, D. Romaguera, J. López-Miranda, R. Estruch, F. J. Tinahones, J. Lapetra, J. L. Serra-Majem, N. Cano-Ibáñez, J. A. Tur, V. Martín-Sánchez, X. Pintó, J. J. Gaforio, P. Matía-Martín, J. Vidal, C. Vázquez, L. Daimiel, E. Ros, S. Jiménez-Murcia, S. Dalsgaard, A. Garcia-Arellano, N. Babio, J. V. Sorli, C. Lassale, M. García-de-la-Hera, E. Gómez-García, M. A. Zulet, J. Konieczna, S. Martín-Peláez, L. Tojal-Sierra, F. J. Basterra-Gortari, S. de las Heras-Delgado, O. Portoles, M. Á. Muñoz-Pérez, A. P. Arenas-Larriva, L. Compañ-Gabucio, S. Eguaras, S. Shyam, M. Fitó, R. M. Baños, J. Salas-Salvadó, F. Fernández-Aranda","doi":"10.1007/s40618-023-02278-y","DOIUrl":"https://doi.org/10.1007/s40618-023-02278-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>To examine the cross-sectional association between baseline depressive symptoms and the presence of type 2 diabetes (T2D), and its association with glycated hemoglobin (HbA1c) and other metabolic variables, and the prospective association of depressive symptoms and HbA1c after 1 year of follow-up.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p><i>n</i> = 6224 Mediterranean older adults with overweight/obesity and metabolic syndrome (48% females, mean age 64.9 ± 4.9 years) were evaluated in the framework of the PREDIMED-Plus study cohort. Depressive symptoms were assessed using the Beck Depression Inventory-II and HbA1c was used to measure metabolic control.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The presence of T2D increased the likelihood of higher levels of depressive symptoms (<i>χ</i>² = 15.84, <i>p</i> = 0.001). Polynomial contrast revealed a positive linear relationship (<i>χ</i>² = 13.49, <i>p</i> = 0.001), the higher the depressive symptoms levels, the higher the prevalence of T2D. Longitudinal analyses showed that the higher baseline depressive symptoms levels, the higher the likelihood of being within the HbA1c ≥ 7% at 1-year level (Wald-<i>χ</i>² = 24.06, <i>df</i> = 3, <i>p</i> &lt; .001, for the full adjusted model). Additionally, depressive levels at baseline and duration of T2D predicted higher HbA1c and body mass index, and lower physical activity and adherence to Mediterranean Diet at 1 year of follow-up.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>This study supports an association between T2D and the severity of depressive symptoms, suggesting a worse metabolic control from mild severity levels in the short–medium term, influenced by lifestyle habits related to diabetes care. Screening for depressive symptoms and a multidisciplinary integrative therapeutic approach should be ensured in patients with T2D.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"79 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139461946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The laywoman church builder Lucrezia Agliarti Vertova (ca 1484–March 24th 1557) had endemic goitre","authors":"R. Bianucci, A. Perciaccante, A. G. Nerlich","doi":"10.1007/s40618-023-02274-2","DOIUrl":"https://doi.org/10.1007/s40618-023-02274-2","url":null,"abstract":"","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"14 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139462141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A machine learning model to predict therapeutic inertia in type 2 diabetes using electronic health record data","authors":"C. C. McDaniel, W.-H. Lo-Ciganic, J. Huang, C. Chou","doi":"10.1007/s40618-023-02259-1","DOIUrl":"https://doi.org/10.1007/s40618-023-02259-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To estimate the therapeutic inertia prevalence for patients with type 2 diabetes, develop and validate a machine learning model predicting therapeutic inertia, and determine the added predictive value of area-level social determinants of health (SDOH).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This prognostic study with a retrospective cohort design used OneFlorida data (linked electronic health records (EHRs) from 1240 practices/clinics in Florida). The study cohort included adults (aged ≥ 18) with type 2 diabetes, HbA1C ≥ 7% (53 mmol/mol), ≥one ambulatory visit, and ≥one antihyperglycemic medication prescribed (excluded patients prescribed insulin before HbA1C). The outcome was therapeutic inertia, defined as absence of treatment intensification within six months after HbA1C ≥ 7% (53 mmol/mol). The predictors were patient, provider, and healthcare system factors. Machine learning methods included gradient boosting machines (GBM), random forests (RF), elastic net (EN), and least absolute shrinkage and selection operator (LASSO). The DeLong test compared the discriminative ability (represented by C-statistics) between models.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The cohort included 31,087 patients with type 2 diabetes (mean age = 58.89 (SD = 13.27) years, 50.50% male, 58.89% White). The therapeutic inertia prevalence was 39.80% among the 68,445 records. GBM outperformed (C-statistic from testing sample = 0.84, 95% CI = 0.83–0.84) RF (C-statistic = 0.80, 95% CI = 0.79–0.80), EN (C-statistic = 0.80, 95% CI = 0.80–0.81), and LASSO (C-statistic = 0.80, 95% CI = 0.80–0.81), <i>p</i> &lt; 0.05. Area-level SDOH significantly increased the discriminative ability versus models without SDOH (C-statistic for GBM = 0.84, 95% CI = 0.84–0.85 vs. 0.84, 95% CI = 0.83–0.84), <i>p</i> &lt; 0.05.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Using EHRs of patients with type 2 diabetes from a large state, machine learning predicted therapeutic inertia (prevalence = 40%). The model’s ability to predict patients at high risk of therapeutic inertia is clinically applicable to diabetes care.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"34 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139070388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of concurrent malignancies in patients with multiple endocrine neoplasia type 1: insights into clinical characteristics of those with multiple endocrine neoplasia type 1","authors":"Yu xing Zhao, Ou Wang, An Song, Lin jie Wang, Feng ying Gong, Lian Duan, Hong bo Yang, Hui Pan, Hui juan Zhu","doi":"10.1007/s40618-023-02288-w","DOIUrl":"https://doi.org/10.1007/s40618-023-02288-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>Summarize and analyze the characteristics of patients with Multiple Endocrine Neoplasia type 1 (MEN-1) who were diagnosed with malignant tumors that do not belong to MEN-1 components.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Clinical data from patients with MEN-1 who visited Peking Union Medical College Hospital between April 2012 and April 2022 were collected. We compared the clinical characteristics of patients with malignant tumors outside of their MEN-1 components to those without additional tumors. MEN-1 gene testing was performed on most of these patients using Sanger sequencing, whole-exome sequencing, or MLPA.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 221 MEN-1 patients were diagnosed, of which 23 (10.40%) were found to have malignant tumors that did not belong to MEN-1 components, including papillary thyroid carcinoma (PTC) (4.52%), breast cancer (1.81%), urologic neoplasms (1.35%), primary hepatic carcinoma (PCC) (0.09%), meningeal sarcoma (0.05%), glioblastoma (0.05%), cervical cancer (0.05%), and lung carcinoma (0.05%). MEN-1 gene mutations were identified in 11 patients, including missense mutations, frameshift mutations, and splice mutations. The prevalence of each endocrine neoplasm, particularly gastroenteropancreatic neuroendocrine tumor, was higher in MEN-1 patients with other malignant tumors compared to MEN-1 patients without malignant tumors.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Our retrospective study revealed a higher incidence of non-MEN-1 component malignant tumors in MEN-1 patients, especially breast cancer, PTC, and urologic neoplasms. These patients also exhibit more severe clinical phenotypes of MEN-1.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"1 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139070066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The direct impact of pegvisomant on osteoblast functions and bone development","authors":"E. Vitali, A. Grasso, M. L. Schiavone, G. Trivellin, C. Sobacchi, M. Mione, G. Mazziotti, A. Lania","doi":"10.1007/s40618-023-02281-3","DOIUrl":"https://doi.org/10.1007/s40618-023-02281-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Acromegaly is a chronic disease characterized by growth hormone (GH) hypersecretion, usually caused by a pituitary adenoma, resulting in elevated circulating levels of insulin-like growth factor type I (IGF-I). Pegvisomant (PEG), the GH-receptor (GHR) antagonist, is used in treating acromegaly to normalize IGF-I hypersecretion. Exposure to increased levels of GH and IGF-I can cause profound alterations in bone structure that are not completely reverted by treatment of GH hypersecretion. Indeed, there is evidence that drugs used for the treatment of acromegaly might induce direct effects on skeletal health regardless of biochemical control of acromegaly.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We investigated, for the first time, the effect of PEG on cell proliferation, differentiation, and mineralization in the osteoblast cell lines MC3T3-E1 and hFOB 1.19 and its potential impact on bone development in zebrafish larvae.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We observed that PEG did not affect osteoblast proliferation, apoptosis, alkaline phosphatase (ALP) activity, and mineralization. After PEG treatment, the analysis of genes related to osteoblast differentiation showed no difference in <i>Alp, Runx2</i>, or <i>Opg</i> mRNA levels in MC3T3-E1 cells. GH significantly decreased cell apoptosis (− 30 ± 11%, p &lt; 0.001) and increased STAT3 phosphorylation; these effects were suppressed by the addition of PEG in MC3T3-E1 cells. GH and PEG did not affect <i>Igf-I</i>, <i>Igfbp2</i>, and <i>Igfbp4</i> mRNA levels in MC3T3-E1 cells. Finally, PEG did not affect bone development in zebrafish larvae at 5 days post-fertilization.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study provides a first evidence of the impact of PEG on osteoblast functions both in vitro and in vivo. These findings may have clinically relevant implications for the management of skeletal health in subjects with acromegaly. </p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"77 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139070633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MKRN3 circulating levels in girls with central precocious puberty caused by MKRN3 gene mutations","authors":"F. Aiello, S. Palumbo, G. Cirillo, G. Tornese, D. Fava, M. Wasniewska, M. F. Faienza, M. Bozzola, C. Luongo, A. Festa, E. Miraglia del Giudice, A. Grandone","doi":"10.1007/s40618-023-02255-5","DOIUrl":"https://doi.org/10.1007/s40618-023-02255-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p><i>MKNR3</i> is a paternally expressed gene whose mutations are the main cause of central precocious puberty (CPP). Protein circulating levels can be easily measured, as demonstrated in idiopathic CPP and healthy controls. No data are available for patients harboring an <i>MKRN3</i> mutation. Our aim was to perform <i>MKRN3</i> mutation screening and to investigate if circulating protein levels could be a screening tool to identify <i>MKRN3</i> mutation in CPP patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We enrolled 140 CPP girls and performed <i>MKRN3</i> mutation analysis. Patients were stratified into two groups: idiopathic CPP (iCPP) and MKRN3 mutation-related CPP (MKRN3-CPP). Clinical characteristics were collected. Serum MKRN3 values were measured by a commercially available ELISA assay kit in MKRN3-CPP and a subgroup of 15 iCPP patients.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We identified 5 patients with <i>MKRN3</i> mutations: one was a novel mutation (p.Gln352Arg) while the others were previously reported (p.Arg328Cys, p.Arg345Cys, p.Pro160Cysfs*14, p.Cys410Ter). There was a significant difference in circulating MKRN3 values in MKRN3-CPP compared to iCPP (<i>p</i> &lt; 0.001). In MKRN3-CPP, the subject harboring Pro160Cysfs*14 presented undetectable levels. Subjects carrying the missense mutations p.Arg328Cys and p.Gln352Arg showed divergent circulating protein levels, respectively 40.56 pg/mL and undetectable. The patient with the non-sense mutation reported low but measurable MKRN3 levels (12.72 pg/mL).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p><i>MKRN3</i> defect in patients with CPP cannot be predicted by MKRN3 circulating levels, although those patients presented lower protein levels than iCPP. Due to the great inter-individual variability of the assay and the lack of reference values, no precise cut-off can be identified to suspect MKRN3 defect.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"13 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acromegaly presented with acne vulgaris: a retrospective study with 123 cases","authors":"X. Wang, M. J. Fan, Y. F. Yu, X. Y. Fan, J. Chen, Y. F. Lai, Y. Liu, H. Y. Ye, Z. Y. Zhang, Y. Zhao, Y. F. Wang, L. H. Xiang, M. He, Y. Ma","doi":"10.1007/s40618-023-02254-6","DOIUrl":"https://doi.org/10.1007/s40618-023-02254-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Acne vulgaris is a prevalent skin condition. We have found that some acromegaly patients have acne. However, no study has examined the relationship between acromegaly and acne.</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To explore prevalence and correlation of adult acne in patients with acromegaly.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>For this cross-sectional study, we collected questionnaires, clinical information, and laboratory test results of acromegaly patients from January 2022 to December 2022 at Huashan Hospital. Of the 133 questionnaires returned, 123 had valid responses.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 123 patients with acromegaly enrolled in this study, 54.5% had adult acne. No statistically significant difference was found in prevalence between male and female patients. 61.2% of adult acne patients reported late-onset acne. Late-onset acne patients first developed acne years before acromegaly diagnosis (mean of 5.6 years for male and 4.5 years for female patients). Some acne patients have received traditional anti-acne treatment. Moreover, 31% of the patients reported no improvement, and only 3.5% of patients claimed complete resolution of acne after treatment. Before acromegaly treatment, the prevalence of adult acne was 51.2%, with mild acne accounting for 73.0%, moderate acne accounting for 23.8%, and severe acne accounting for 3.2%. After acromegaly treatment, the prevalence of adult acne was significantly decreased to 37.4% (<i>P</i> = 0.007). An overall decrease in acne severity was noted, with 93.5%, 6.5%, and 0% having mild, moderate, and severe acne, respectively. A total of 83.6% of the patients had self-assessed acne remission, and 33.3% of the patients reported complete acne resolution. However, 9.0% of patients reported that their condition had worsened after acromegaly treatment. After treatment, GH, IGF-1, IGF-1 index, insulin levels, and HOMA-IR decreased significantly in all patients with acromegaly (<i>P</i> &lt; 0.05). Acne remission correlated positively with IGF-1 levels, but not with GH levels. The relationship between acromegaly and acne remains to be elucidated.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Our findings provide preliminary evidence of the high prevalence of adult acne in acromegaly patients, and a high rate of late-onset acne as well. Traditional anti-acne treatments are less effective. Acne could be considerably relieved by treating acromegaly. Acne remission positively correlated with IGF-1 decline as well, which revealed the correlation between acne and IGF-1.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"31 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus","authors":"Y. Suzuki, H. Kaneko, A. Okada, R. Ohno, I. Yokota, K. Fujiu, T. Jo, N. Takeda, H. Morita, K. Node, H. Yasunaga, I. Komuro","doi":"10.1007/s40618-023-02246-6","DOIUrl":"https://doi.org/10.1007/s40618-023-02246-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aimed to examine the potential benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors for patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and diabetes mellitus (DM) using a real-world database.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We analyzed individuals with MAFLD and DM newly initiated on SGLT2 or dipeptidyl peptidase 4 (DPP4) inhibitors from a large-scale administrative claims database. The primary outcome was the change in the fatty liver index (FLI) assessed using a linear mixed-effects model from the initiation of SGLT2 or DPP4 inhibitors. A propensity score-matching algorithm was used to compare the change in FLI among SGLT2 and DPP4 inhibitors.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>After propensity score matching, 6547 well-balanced pairs of SGLT2 and 6547 DPP4 inhibitor users were created. SGLT2 inhibitor use was associated with a greater decline in FLI than DPP4 inhibitor use (difference at 1-year measurement, − 3.8 [95% CI − 4.7 to − 3.0]). The advantage of SGLT2 inhibitor use over DPP4 inhibitor use for improvement in FLI was consistent across subgroups. The relationship between SGLT2 inhibitors and amelioration of FLI was comparable between individual SGLT2 inhibitors.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Our analysis using large-scale real-world data demonstrated the potential advantage of SGLT2 inhibitors over DPP4 inhibitors in patients with MAFLD and DM.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"111 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does vitamin D deficiency affect functional outcomes in hip fracture patients? A meta-analysis of cohort studies","authors":"R. Llombart, G. Mariscal, C. Barrios, J. E. de la Rubia Ortí, R. Llombart-Ais","doi":"10.1007/s40618-023-02266-2","DOIUrl":"https://doi.org/10.1007/s40618-023-02266-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Vitamin D deficiency is common in patients with hip fractures and may negatively affect functional recovery and quality of life (QOL).</p><h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study aimed to conduct a meta-analysis to quantify the effects of vitamin D deficiency on physical function and quality of life after hip fractures.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The PubMed, EMBASE, Scopus, and Cochrane Library databases were searched for relevant studies. The inclusion criteria were hip fracture, comparison between vitamin D deficiency and normal vitamin D levels in patients with hip fracture, and functional outcome as the primary outcome. The exclusion criteria were case reports, reviews, duplicates, studies with a high risk of bias, and non-comparable or missing data. Two independent reviewers selected studies, extracted data, assessed bias, and performed meta-analyses using the Review Manager. Heterogeneity and publication bias were also assessed. Two independent reviewers selected the studies, extracted data, and assessed the risk of bias. We performed a meta-analysis using Review Manager and assessed heterogeneity and publication bias.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Seven studies with 1,972 patients were included. Vitamin D deficiency was defined as a 25(OH)D level &lt; 20 ng/mL. There were no significant differences in the ability to walk (OR 0.68, 95% CI 0.31–1.53, I² = 69%) or length of hospital stay (MD 2.27 days, 95% CI − 2.47 to 7.01, I² = 93%) between patients with and without vitamin D deficiency. However, patients with vitamin D deficiency had significantly worse functional ability and quality of life (SMD − 1.50, 95% CI − 2.88 to − 0.12, I² = 96%).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Despite the limitations of this study, such as small sample size, heterogeneous outcome assessments, and variable vitamin D measurement techniques, the results demonstrated that screening for vitamin D status and optimizing levels through supplementation could facilitate rehabilitation, promote lifestyle changes, aid in the recovery of independence, and help reduce long-term burdens.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"39 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation study between bone metabolic markers, bone mineral density, and sarcopenia","authors":"W. Xie, M. He, D. Yu, H. Li, H. Jin, B. Ji, G. Yang, L. Chen, M. Rahmati, Y. Li","doi":"10.1007/s40618-023-02252-8","DOIUrl":"https://doi.org/10.1007/s40618-023-02252-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To investigate the correlation between bone metabolism markers, bone mineral density (BMD), and sarcopenia.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A total of 331 consecutive patients aged ≥ 60 years who were hospitalized between November 2020 and December 2021 were enrolled. Participants were divided into sarcopenia and non-sarcopenia groups according to the Asian Working Group on Sarcopenia criteria (AWGS, 2019). The clinical data, bone metabolism markers (β-CTX, N-MID, and TP1NP), and BMD were compared between the two groups.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Age, β-CTX, and N-MID of the sarcopenia group were higher than those of the non-sarcopenia group (<i>P</i> &lt; 0.05), but the BMD <i>T</i> values were lower than those of the non-sarcopenia group (<i>P</i> &lt; 0.05). Binary logistic regression analysis showed that increased femoral neck BMD (FNBMD) was a protective factor for sarcopenia, while increased β-CTX was a risk factor. Pearson/Spearman correlation analysis showed that the diagnostic indices of sarcopenia were positively correlated with FNBMD and negatively correlated with β-CTX and N-MID. Multiple linear regression analysis revealed that BMI and FNBMD significantly positively affected muscle strength and appendicular skeletal muscle mass (ASM). The FNBMD significantly positively affected physical performance, while β-CTX significantly negatively affected muscle strength, ASM, and physical performance.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Increased FNBMD may be a protective factor against sarcopenia, and increased β-CTX may be a risk factor. The FNBMD significantly positively affected the diagnostic indices of sarcopenia, while β-CTX significantly negatively affected them. BMD and bone metabolism marker levels may be considered in early screening for sarcopenia.</p>","PeriodicalId":15651,"journal":{"name":"Journal of Endocrinological Investigation","volume":"59 1","pages":""},"PeriodicalIF":5.4,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138679858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}